Wendy Vogel, executive director of the Advanced Practitioner Society for Hematology and Oncology (APSHO) discusses the Make It HAPPen™ campaign and the recent survey that validated the impact APPs have on multiple myeloma patient journeys as well as the need to provide APPs with further educational resources.
INTERVIEWS
Hot Topics Following the 2023 American Academy of Head and Neck Surgery Conference
Dr. Dan Faden, Specialist and Investigator in Head and Neck Surgery at Massachusetts General Brigham Mass Eye & Ear discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference titled Ten Hot Topics in Head and Neck Surgical Oncology Panel and Great Debates: ctDNA: Is It Ready for Prime Time?
Atrial Fibrillation (AFib) Awareness
Dr. Khaldoun Tarakji, Vice President and Chief Medical Officer of the Cardiac Ablation Solutions (CAS) Operating Unit (OU) at Medtronic discusses signs and symptoms of AFib and the latest innovations and advancements related to AFib.
Spectral AI – Advancing AI-driven Burn Wound Imaging Technology
Wensheng Fan, CEO and co-founder of Spectral AI, a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView � System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). DeepView ® records imaging data of the wound and uses an AI algorithm to predict wound healing patterns based on a large proprietary clinical database.
Invivyd, Inc – Development of a Monoclonal Antibody for COVID-19 Prevention in Vulnerable Populations
Dave Hering, CEO of Invivyd, Inc, a biopharmaceutical company discusses the development of a monoclonal antibody to prevent COVID-19 in immunocompromised people, through their pivotal Phase 3 trial called CANOPY. This is the final step in a rapid development program for an antibody infusion to prevent symptomatic COVID-19 in vulnerable populations.
Eye Corps – Working to End Preventable Blindness in Rural Sub-Saharan Africa
Dr. Susan MacDonald, MD, board-certified ophthalmologist, Co-founder and CEO of Eye Corps discusses Eye Corps’ mission to eliminate preventable blindness in sub-Saharan Africa through strategic partnerships with the local medical community and ophthalmic training institutions. Eye Corps works to build a sustainable infrastructure for eye care delivery in sub-Saharan Africa with a focus on eliminating gender inequity in vision care.
GE HealthCare – Reimagining Better Health
Andy DeLaO, Chief Strategy & Marketing Officer at GE HealthCare U.S. and Canada, discusses findings from “Reimagining Better Health,” GE HealthCare’s first-ever international study on the state of healthcare. The study amplifies the united perspectives of patients and clinicians who envision a more human and flexible healthcare experience.
Schizophrenia Awareness and New Long-Acting Treatment
Dr. Christoph Correll, Professor of Psychiatry at the Zucker School of Medicine discusses common misconceptions about schizophrenia and the challenges that people experience when managing this condition, including adherence to medication and the risk of relapse. Dr. Correll also discusses a recently-approved treatment for adults with schizophrenia called UZEDY™ (risperidone) extended-release injectable suspension, and new data that build on our existing knowledge about this treatment option.
A New Breakthrough in Early Detection of Alzheimer’s Disease Risk
Dr. Michael Racke, a board-certified neurologist and medical director of neurology at Quest Diagnostics, discusses the advances in blood and other tests for Alzheimer’s Disease. He’ll also talk about other practical ways to talk to healthcare providers about the disease, new research that shows how lifestyle changes may reduce risk, and questions people should ask their doctor to assess their own risk. For more information visit questforthecure.com
AstraZeneca – Trial Data for Gastric and Gastroesophageal Junction Cancers
Shubh Goel, VP, Head of Immuno-Oncology and GI Tumors Franchise at AstraZeneca discusses data presented at the European Society for Medical Oncology (ESMO) 2023 from the MATTERHORN Phase 3 trial data where patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction cancers are treated with IMFINZI ® (durvalumab) + chemotherapy in the perioperative setting.